Optimizing care of patients with ALS: Steps to early detection and improved quality of life

Postgraduate Medicine

Volumn 105, Issue 4, 1999, Pages 143-156

  Mackin, Glenn A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BACLOFEN; CHOLINERGIC RECEPTOR BLOCKING AGENT; GROWTH FACTOR; LAXATIVE; NEUROTROPHIN; RILUZOLE; TRICYCLIC ANTIDEPRESSANT AGENT;

AMYOTROPHIC LATERAL SCLEROSIS; CAREGIVER; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; EARLY DIAGNOSIS; ELECTROMYOGRAPHY; HUMAN; NERVE CONDUCTION; PATIENT CARE; PRIMARY MEDICAL CARE; QUALITY OF LIFE; REVIEW; TREATMENT PLANNING;

EID: 0033012445     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.1999.04.676     Document Type: Review

References (17)

1. Mitsumoto H. Classification and clinical features of amyotrophic lateral sclerosis. In: Mitsumoto H, Norris FH, eds. Amyotrophic lateral sclerosis: a comprehensive guide to management. New York: Demos, 1994:1-19
2. Brooks BR. Natural history of ALS: symptoms, strength, pulmonary function, and disability. Neurology 1996;47(4 Suppl 2):S71-81
3. Klein LM, Forshew DA. The economic impact of ALS. Neurology 1996;47(4 Suppl 2):S126-9
4. Behnia M, Kelly JJ. Role of electromyography in amyotrophic lateral sclerosis. Muscle Nerve 1991;14(12):1236-41
5. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. J Neurol Sci 1994;124 Suppl:96-107
6. Belsh JM. Differential diagnosis of ALS. Part I. Non-motor neuron diseases and adult-onset spinal muscular atrophies. In: Belsh JM, Schiffman PL, eds. Amyotrophic lateral sclerosis: diagnosis and management for the clinician. Armonk, NY: Futura, 1996:85-129
7. 6 pp 131-61
8. Bensimon G, Lacomblez L, Meininger V, for the ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330(9): 585-91
9. Lacomblez L, Bensimon G, Leigh PN, et al, for the Amyotrophic Lateral Sclerosis/ Riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996;347(9013):1425-31
10. Miller RG, Bouchard JP, Duquette P, et al, for the ALS/Riluzole Study Group II. Clinical trials of riluzole in patients with ALS. Neurology 1996;47(4 Suppl 2): S86-90
11. Miller R, Swash M. Therapeutic advances in ALS. Neurology 1996;47(6 Suppl 4):S217
12. Doble A. The pharmacology and mechanism of action of riluzole. Neurology 1996;47(6 Suppl 4):S233-41
13. Wokke J. Riluzole. Lancet 1996;348 (9030):795-9
14. Practice advisory on the treatment of amyotrophic lateral sclerosis with riluzole: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1997;49(3):657-9
15. Riviere M, Meininger V, Zeisser P, et al. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol 1998; 55(4):526-8
16. Mitsumoto H. Riluzole - what is its impact in out treatment and understanding of amyotrophic lateral sclerosis? Ann Pharmacother 1997;31(6):779-81
17. Mitsumoto H, Olney RK. Drug combination treatment in patients with ALS: current status and future directions. Neurology 1996;47(4 Suppl 2):S103-7